Drug Insights

Is Rezafungin approved by the FDA?

1 August 2024
2 min read

Rezafungin, marketed under the brand name Rezzayo, was approved by the FDA on March 22, 2023, for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options. This approval was based on limited clinical safety and efficacy data.

Usage and Dosage

Rezafungin is administered as an intravenous infusion, usually once per week. The standard dosing regimen involves an initial loading dose of 400 mg followed by a maintenance dose of 200 mg once a week. Each infusion is given slowly over approximately one hour.

Side Effects

Common side effects of rezafungin may include:

  • Low blood levels of potassium, phosphate, or magnesium
  • Diarrhea, nausea, vomiting
  • Constipation, stomach pain
  • Pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet
  • Fever

Some side effects may occur during the injection, such as dizziness, nausea, light-headedness, itching, sweating, headache, chest tightness, back pain, trouble breathing, or swelling in the face.

Serious side effects requiring immediate medical attention include:

  • Severe allergic reactions
  • Low blood potassium or magnesium levels
  • Low blood phosphate levels

Warnings and Precautions

Before starting rezafungin, it is important to inform your doctor if you have:

  • A history of liver disease
  • Any allergies to rezafungin or similar medications (anidulafungin, caspofungin, micafungin)

It is not known if rezafungin will harm an unborn baby, so pregnant women should consult their doctor. Breastfeeding women should also seek medical advice before using this medication.

Interactions

Rezafungin can interact with other medications, including prescription and over-the-counter medicines, vitamins, and herbal products. It is crucial to inform your healthcare provider about all the medications you are currently taking to avoid potential interactions.

Storage

Rezafungin should be stored as per the instructions provided with the medication. Your pharmacist can provide detailed storage information.

Rezafungin offers a promising treatment option for adults with serious candida infections, especially those with limited alternatives. Always follow your healthcare provider's instructions and report any side effects or concerns promptly.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Chemomab Therapeutics Reveals Successful Phase 2 Study Outcomes: CM-101 Meets Key Targets
Latest Hotspot
4 min read
Chemomab Therapeutics Reveals Successful Phase 2 Study Outcomes: CM-101 Meets Key Targets
1 August 2024
Chemomab Therapeutics Announces Positive Results in Phase 2 Study: CM-101 Demonstrates Anti-Fibrotic, Anti-Inflammatory, and Anti-Cholestatic Effects in Primary Sclerosing Cholangitis.
Read →
Is Trofinetide approved by the FDA?
Drug Insights
4 min read
Is Trofinetide approved by the FDA?
1 August 2024
The FDA approved Daybue on March 10, 2023, for the treatment of Rett syndrome in adults and children aged 2 years and older.
Read →
FDA Approves BioMarin's BRINEURA® for CLN2 Disease in Children Under 3
Latest Hotspot
3 min read
FDA Approves BioMarin's BRINEURA® for CLN2 Disease in Children Under 3
1 August 2024
The FDA has approved BioMarin's BRINEURA® (cerliponase alfa) for treating children under 3 years old with CLN2 disease.
Read →
Is Omaveloxolone approved by the FDA?
Drug Insights
3 min read
Is Omaveloxolone approved by the FDA?
31 July 2024
The FDA approved Skyclarys on February 28, 2023, for the treatment of Friedreich's ataxia in adults and teenagers 16 years and older.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.